Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026 (IMAGE)
Caption
At 130 mg once daily, ORR was 40.0% (two of five response-evaluable participants), with target-lesion reductions of 58% and 36%. Across 30–130 mg, mesothelioma ORR was 18.2% (four of 22 response-evaluable participants) and disease control rate (DCR) 68.2%, with responses at 30, 50, and 130 mg; three of four responders showed responses at the first Week-8 scan; partial responses were observed after five and six prior lines; three of four partial responses were ongoing at cutoff, including one lasting approximately one year.
Signal beyond mesothelioma included target-lesion shrinkage in heavily pretreated non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (seven and eight prior lines) and stable disease beyond four months in epithelioid hemangioendothelioma and colorectal cancer.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content